Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q3 2024 · 10-Q
Revenue$155.10M$155.10M+21.8% vs Q3 2023 Net Income-$30.57M-$30.57MN/M vs Q3 2023 EPS Diluted-$0.28-$0.28N/M vs Q3 2023 Gross Profit$119,723,000+25.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$10,376,000N/M Free Cash Flowderived-$307,000N/M Margins · derivedGross margin77.2%+2.4 pt vs Q3 2023
Operating margin-20.7%+25.1 pt vs Q3 2023
Net margin-19.7%+19.2 pt vs Q3 2023
ended Sep 30, 2024 · filed Oct 30, 2024 · 30 d after period end